{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:48:12Z","timestamp":1788356892180,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,12,20]],"date-time":"2008-12-20T00:00:00Z","timestamp":1229731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1007\/s00213-008-1433-z","type":"journal-article","created":{"date-parts":[[2008,12,19]],"date-time":"2008-12-19T18:37:26Z","timestamp":1229711846000},"page":"37-48","source":"Crossref","is-referenced-by-count":23,"title":["WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics"],"prefix":"10.1007","volume":"204","author":[{"given":"Steven M.","family":"Grauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheree F.","family":"Logue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Stack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Huselton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Comery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Marquis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Rosenzweig-Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,20]]},"reference":[{"key":"1433_CR1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Mooseong H, Chander LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686\u20131696","journal-title":"Am J Psychiatry"},{"key":"1433_CR2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1744-6163.2004.00070.x","volume":"40","author":"D Antai-Otong","year":"2004","unstructured":"Antai-Otong D (2004) Metabolic effects associated with atypical antipsychotic medications. Perspectives in Psychiatric Care 40:70\u201372","journal-title":"Perspectives in Psychiatric Care"},{"key":"1433_CR3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0773.1982.tb01032.x","volume":"51","author":"J Arnt","year":"1982","unstructured":"Arnt J (1982) Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51:321\u2013329","journal-title":"Acta Pharmacol Toxicol"},{"key":"1433_CR4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/met.2004.2.290","volume":"2","author":"T Baptista","year":"2004","unstructured":"Baptista T, De Mendoza S, Beaulieu S et al (2004) The metabolic syndrome during atypical antipsychotic drug treatment: mechanism and management. Metabolic Syndrome and Related Disorders 2:290\u2013307","journal-title":"Metabolic Syndrome and Related Disorders"},{"key":"1433_CR5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbr.2003.11.001","volume":"153","author":"KE Browman","year":"2004","unstructured":"Browman KE, Komater VA, Curzon P, Rueter LE, Hancock AA, Decker MW, Fox GB (2004) Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan. Behav Brain Res 153:69\u201376","journal-title":"Behav Brain Res"},{"key":"1433_CR6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1017\/S0033291700038228","volume":"22","author":"A Buchanan","year":"1992","unstructured":"Buchanan A (1992) A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 22:787\u2013797","journal-title":"Psychol Med"},{"issue":"Suppl","key":"1433_CR7","first-page":"s40","volume":"57","author":"DE Casey","year":"1996","unstructured":"Casey DE (1996) Side effects of new antipsychotic agents. J Clin Psych 57(Suppl):s40\u2013s45","journal-title":"J Clin Psych"},{"key":"1433_CR8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1196\/annals.1300.020","volume":"1003","author":"JT Coyle","year":"2003","unstructured":"Coyle JT, Tsai G, Goff D (2003) Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad Sci 1003:318\u2013327","journal-title":"Ann NY Acad Sci"},{"key":"1433_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(75)90072-2","volume":"31","author":"B Costall","year":"1975","unstructured":"Costall B, Naylor RJ, Neumeyer (1975) Differences in the nature of stereotyped behaviour induced by apomorphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas. Eur J Pharmacol 31:1\u201316","journal-title":"Eur J Pharmacol"},{"key":"1433_CR10","first-page":"175P","volume":"68","author":"B Costall","year":"1980","unstructured":"Costall B, Naylor RJ, Nohria V (1980) On the importance of mesolimbic mechanisms for the control of apomorphine induced climbing behaviour in the mouse. Br J Pharmacol 68:175P\u2013176P","journal-title":"Br J Pharmacol"},{"key":"1433_CR11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hup.470100504","volume":"10","author":"PJ Cowen","year":"1995","unstructured":"Cowen PJ, Sargent PA, Williams C, Goodall EM, Orlikov AB (1995) Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women. Hum Psychopharmacol 10:385\u2013391","journal-title":"Hum Psychopharmacol"},{"key":"1433_CR12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004714-200206000-00003","volume":"22","author":"P Czobor","year":"2002","unstructured":"Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Cooper TB, Chakos M, Lieberman JA (2002) Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Pyschopharmacol 22:244\u2013251","journal-title":"J Clin Pyschopharmacol"},{"key":"1433_CR13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/(SICI)1098-2396(200001)35:1<53::AID-SYN7>3.0.CO;2-2","volume":"35","author":"G Giovanni Di","year":"2000","unstructured":"Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin 2C\/2B receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53\u201361","journal-title":"Synapse"},{"key":"1433_CR14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/jpet.104.075382","volume":"313","author":"J Dunlop","year":"2005","unstructured":"Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonkers S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, Harrison BL, Rosenzweig-Lipson S (2005) WAY-163909 ((7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole), a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther 313:862\u2013869","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1433_CR15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1527-3458.2006.00167.x","volume":"12","author":"J Dunlop","year":"2006","unstructured":"Dunlop J, Marquis K, Lim HK, Leung L, Kao J, Cheesman C, Rosenzweig-Lipson (2006) Pharmacological profile of the 5-HT2C receptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug Reviews 12(3):167\u2013176","journal-title":"CNS Drug Reviews"},{"issue":"Suppl","key":"1433_CR16","first-page":"s20","volume":"60","author":"J Gerlach","year":"1999","unstructured":"Gerlach J (1999) The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 60(Suppl):s20\u2013s23","journal-title":"J Clin Psychiatry"},{"key":"1433_CR17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0924-9338(99)00228-X","volume":"14","author":"M Gervin","year":"1999","unstructured":"Gervin M, Browne J, Garavan M, Roe C, Larkin C, Callaghan O (1999) Dysphoric subjective response to antipsychotics in schizophrenia: relationship to extrapyramidal side-effects and symptomatology. Eur Psychiatry 14:405\u2013409","journal-title":"Eur Psychiatry"},{"key":"1433_CR18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","volume":"156","author":"MA Geyer","year":"2001","unstructured":"Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenics: as decade in review. Psychopharmacology 156:117\u2013154","journal-title":"Psychopharmacology"},{"key":"1433_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002130050165","volume":"129","author":"SD Gleason","year":"1997","unstructured":"Gleason SD, Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129:79\u201384","journal-title":"Psychopharmacology"},{"issue":"1","key":"1433_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.schres.2005.08.010","volume":"80","author":"DC Goff","year":"2005","unstructured":"Goff DC, Sullivan L, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D\u2019Agostino RB, Stroup TS, Davis S, Lieberman JA (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80(1):45\u201353","journal-title":"Schizophr Res"},{"key":"1433_CR21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02246184","volume":"120","author":"DC Hoffman","year":"1995","unstructured":"Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120:128\u2013133","journal-title":"Psychopharmacology"},{"key":"1433_CR22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","volume":"52","author":"S Kapur","year":"2001","unstructured":"Kapur S, Remington G (2001) Aytpical antipsychotics: new directions and challenges in the treatment of schizophrenia. Annu Rev Med 52:503\u2013517","journal-title":"Annu Rev Med"},{"key":"1433_CR23","first-page":"52S","volume":"8","author":"J Kane","year":"1998","unstructured":"Kane J, Woerner MG, Lieberman J (1998) Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 8:52S\u201362S","journal-title":"J Clin Psychopharmacol"},{"key":"1433_CR24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/bmj.325.7358.243","volume":"325","author":"CE Koro","year":"2002","unstructured":"Koro CE, Fedder DO, L\u2019Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Rivicki DA, Buchanan RW (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325:243\u2013245","journal-title":"BMJ"},{"key":"1433_CR25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1568007043482598","volume":"3","author":"JE Leysen","year":"2004","unstructured":"Leysen JE (2004) 5-HT2 receptors. Curr Drug Targ CNS Neurolog Disord 3:11\u201326","journal-title":"Curr Drug Targ CNS Neurolog Disord"},{"issue":"12","key":"1433_CR26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209\u20131223","journal-title":"N Engl J Med"},{"key":"1433_CR27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/jpet.106.106989","volume":"320","author":"KL Marquis","year":"2007","unstructured":"Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S (2007) WAY-163909 ((7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole): a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486\u2013496","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1433_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"JP McEvoy","year":"2005","unstructured":"McEvoy JP, Meyer JM, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparisons with national estimates from NHANES III. Schizophr Res 80(1):19\u201332","journal-title":"Schizophr Res"},{"key":"1433_CR29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2003.09.010","volume":"4","author":"HY Meltzer","year":"2004","unstructured":"Meltzer HY (2004) What\u2019s atypical about atypical antipsychotic drugs. Curr Op in Pharmacol 4:53\u201357","journal-title":"Curr Op in Pharmacol"},{"issue":"Suppl","key":"1433_CR30","first-page":"s27","volume":"62","author":"JM Meyer","year":"2001","unstructured":"Meyer JM (2001) Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 62(Suppl):s27\u2013s41","journal-title":"J Clin Psychiatry"},{"key":"1433_CR31","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0028-3908(98)00078-1","volume":"37","author":"MJ Millan","year":"1998","unstructured":"Millan MJ, Dekeyne A, Gobert A (1998) Serotonin 5-HT2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA) but not 5-HT release in the frontal cortex in vivo. Neuropharmacol 37:953\u2013955","journal-title":"Neuropharmacol"},{"issue":"6","key":"1433_CR32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.biopsych.2005.07.035","volume":"59","author":"S Navailles","year":"2006","unstructured":"Navailles S, De Deurwaerdere P, Spampinato U (2006) Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo. Biological Psychiatry. 59(6):568\u2013575","journal-title":"Biological Psychiatry."},{"issue":"10","key":"1433_CR33","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/2647","volume":"4","author":"K Nonogaki","year":"1998","unstructured":"Nonogaki K, Strack AM, Dallman MF, Tecott LH (1998) Leptin-independent hyperphagia and Type 2 diabetes in mice with mutated serotonin 5-HT2C receptor gene. Nat Med 4(10):1152\u20131156","journal-title":"Nat Med"},{"key":"1433_CR34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/070674370104600308","volume":"46","author":"SM Roger","year":"2001","unstructured":"Roger SM, McCann SM, Kennedy SH (2001) Antipsychotic metabolic effects: diabetes mellitus and lipid abnormalities. Can J Psychiatry 46:273\u2013280","journal-title":"Can J Psychiatry"},{"key":"1433_CR35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psych 56:241\u2013247","journal-title":"Arch Gen Psych"},{"key":"1433_CR36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.brainres.2005.12.052","volume":"1073\u20131074","author":"S Rosenzweig-Lipson","year":"2006","unstructured":"Rosenzweig-Lipson S, Zhang J, Mazandarani H, Harrison BL, Sabb A, Sabalski J, Stack G, Welmaker G, Barrett JE, Dunlop J (2006) Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161505. Brain Res 1073\u20131074:240\u2013251","journal-title":"Brain Res"},{"issue":"2","key":"1433_CR37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00213-007-0710-6","volume":"192","author":"S Rosenzweig-Lipson","year":"2007","unstructured":"Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg J, Grauer S, Brennan J, Cryan JF, Rizzo SJS, Dunlop J, Barrett JE, Marquis KL (2007) Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology 192(2):159\u2013170","journal-title":"Psychopharmacology"},{"key":"1433_CR38","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/sj.npp.1300591","volume":"30","author":"CS Shilliam","year":"2005","unstructured":"Shilliam CS, Dawson LA (2005) The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT(2C) receptor antagonist. Neuropsychopharmacol 30:372\u2013380","journal-title":"Neuropsychopharmacol"},{"key":"1433_CR39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-0447.2000.101006416.x","volume":"101","author":"DM Taylor","year":"2000","unstructured":"Taylor DM, McAskill R (2000) Atypical antipsychotics and weight gain\u2014a systematic review. Acta Psychiatrica Scandinavica 101:416\u2013432","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"1433_CR40","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.euroneuro.2006.06.005","volume":"16","author":"LF Gaal Van","year":"2006","unstructured":"Van Gaal LF (2006) Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity. Eur Neuropsychopharmacol 16:S142\u2013S148","journal-title":"Eur Neuropsychopharmacol"},{"key":"1433_CR41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archpsyc.1974.01760130049008","volume":"31","author":"T Putten Van","year":"1974","unstructured":"Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs. Arch Gen Psych 31:67\u201372","journal-title":"Arch Gen Psych"},{"key":"1433_CR42","first-page":"105","volume":"14","author":"JL Young","year":"1986","unstructured":"Young JL, Zonana HV, Shepler L (1986) Medication non-compliance in schizophrenia: codification and update. Bull Am Acad Psych Law 14:105\u2013122","journal-title":"Bull Am Acad Psych Law"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-008-1433-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-008-1433-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-008-1433-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T02:39:36Z","timestamp":1684809576000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-008-1433-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,20]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["1433"],"URL":"https:\/\/doi.org\/10.1007\/s00213-008-1433-z","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,20]]}}}